Vous n'êtes pas connecté
Rubriques :
- HEALTHTECHZONE.COM - Medical Devices - 03/Sep 13:00
Kardium receives FDA approval of the Globe® Pulsed Field System
Articles similaires
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Monthly News Roundup - August 2025
Wegovy Granted Accelerated Approval as First GLP-1 Treatment for the Treatment of MASH Novo Nordisk’s Wegovy (semaglutide) has received US Food...
Monthly News Roundup - August 2025
Wegovy Granted Accelerated Approval as First GLP-1 Treatment for the Treatment of MASH Novo Nordisk’s Wegovy (semaglutide) has received US Food...
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating...
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating...
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Les derniers communiqués
-
Secretary Noem Fires FEMA Employees Who Used Government Devices to Consume Racially Charged Porn During Work Hours
The Department of homeland security - 02/09/2025
-
DHS Announces New Reimbursement Opportunities for State and Local Law Enforcement Partnering with ICE to Arrest the Worst of the Worst Criminal Illegal Aliens
The Department of homeland security - 02/09/2025
-
On Labor Day, DHS Secretary Kristi Noem Celebrates the 2.5 Million American Workers Who Joined the Workforce Since Trump Took Office
The Department of homeland security - 01/09/2025
-
CBS Deceptively Edits Secretary Noem’s Answers, Cutting More than 23% of Footage from Face the Nation Interview
The Department of homeland security - 31/08/2025
-
Hanwha announces $5 billion Philly Shipyard investment as part of S. Korea's commitment to U.S. shipbuilding growth
Hanwha Group - 27/08/2025
-
QuickLogic Showcases eFPGA Hard IPs at GlobalFoundries Technology Summit
QuickLogic Corporation - 27/08/2025
-
Guidehouse Research Expects Global Market for Data Center Cooling to Surpass $40 Billion by 2034
Guidehouse - 27/08/2025
-
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
Rosen Law Firm - 26/08/2025
-
Global Digital Biomarkers Market Anticipating Remarkable Growth at a CAGR of ~17% by 2032 | DelveInsight
DelveInsight Business Research, LLP - 26/08/2025
-
Consumer Watchdog Joins Amicus Brief To Protect Consumers' Privacy And Keep California Courthouse Doors Open
Consumer Watchdog - 26/08/2025